My favorite companion on woodland hikes (other than my wife and dogs) is my Leatherman, the ultimate multitool.  It seems that the biologic agent dupilumab (Dupixent) is also becoming a multitool.  It was initially approved by the FDA for people with severe eczema (atopic dermatitis).  It works by preventing the inflammatory eosinophils from entering the skin.  But since eosinophils also cause other types of allergic inflammation dupilumab’s role has expanded to include severe asthma, chronic rhinosinusitis with polyposis, eosinophilic esophagitis, and urticaria.  It is both an expensive and potent medicine so it is not considered a first line treatment for any of these conditions.